Login / Signup

Long term survival in multiple myeloma: a single institution experience in underprivileged circumstances.

Lorena Bojalil-AlvarezMorie A GertzElizabeth Garcia-VillaseñorJosé Antonio Fernández-GutiérrezOscar Alfonso Reyes-CisnerosIvan MurrietaYahveth Cantero-FortizGuillermo J Ruiz-DelgadoGuillermo José Ruiz-Arguelles
Published in: Leukemia & lymphoma (2021)
There is data suggesting that the clinical behavior of multiple myeloma (MM) may be different in Latin Americans than in Caucasian or African-Americans, consistent with a less aggressive course of MM in Latinos. We analyzed the overall survival (OS) of 139 persons with MM in a single institution in México, as well the variables which were associated with long-term OS. Of all patients, the median OS was 11 years whereas the 5-year and 10-year OS were 75% and 55% respectively. The analysis of variables showed that the variable related with five-year survival was having hematopoietic stem cell transplantation (HSCT), whereas the variables related with 10-year survival were HSCT, age at diagnosis (patients younger than 50 survived longer), light chain type (kappa survived longer) and ISS stage (stage I patients survived longer). The only variable associated with both 5 and 10-year survival was HSCT. A plateau in the OS was reached after 10 years, both in grafted and non-grafted patients. We have confirmed the critical role of HSCT in the prognosis of persons with MM, independent of the induction treatment or the maintenance post-transplant, and we have identified a better prognosis in this cohort, as compared with African-Americans or Caucasians, since the proportion of long-term survivors in our group is seemingly better than those in other populations.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • multiple myeloma
  • prognostic factors
  • young adults
  • toll like receptor
  • patient reported
  • replacement therapy